Researcher profile

Ted Westling

Ted Westling contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate

Trust snapshot

Quick read

Trust 13 - UnverifiedVerification L1Unclaimed author
2works
0followers
2topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

2 published item(s)

preprint2022arXiv

Nonparametric identification of causal effects in clustered observational studies with differential selection

The clustered observational study (COS) design is the observational study counterpart to the clustered randomized trial. In a COS, a treatment is assigned to intact groups, and all units within the group are exposed to the treatment. However, the treatment is non-randomly assigned. COSs are common in both education and health services research. In education, treatments may be given to all students within some schools but withheld from all students in other schools. In health studies, treatments may be applied to clusters such as hospitals or groups of patients treated by the same physician. In this manuscript, we study the identification of causal effects in clustered observational study designs. We focus on the prospect of differential selection of units to clusters, which occurs when the units' cluster selections depend on the clusters' treatment assignments. Extant work on COSs has made an implicit assumption that rules out the presence of differential selection. We derive the identification results for designs with differential selection and that contexts with differential cluster selection require different adjustment sets than standard designs. We outline estimators for designs with and without differential selection. Using a series of simulations, we outline the magnitude of the bias that can occur with differential selection. We then present two empirical applications focusing on the likelihood of differential selection.

preprint2022arXiv

Nonparametric inference under a monotone hazard ratio order

The ratio of the hazard functions of two populations or two strata of a single population plays an important role in time-to-event analysis. Cox regression is commonly used to estimate the hazard ratio under the assumption that it is constant in time, which is known as the proportional hazards assumption. However, this assumption is often violated in practice, and when it is violated, the parameter estimated by Cox regression is difficult to interpret. The hazard ratio can be estimated in a nonparametric manner using smoothing, but smoothing-based estimators are sensitive to the selection of tuning parameters, and it is often difficult to perform valid inference with such estimators. In some cases, it is known that the hazard ratio function is monotone. In this article, we demonstrate that monotonicity of the hazard ratio function defines an invariant stochastic order, and we study the properties of this order. Furthermore, we introduce an estimator of the hazard ratio function under a monotonicity constraint. We demonstrate that our estimator converges in distribution to a mean-zero limit, and we use this result to construct asymptotically valid confidence intervals. Finally, we conduct numerical studies to assess the finite-sample behavior of our estimator, and we use our methods to estimate the hazard ratio of progression-free survival in pulmonary adenocarcinoma patients treated with Gefitinib or carboplatin-paclitaxel.